Dermatological Drugs Market Report and Forecast 2025-2034
Description
The global dermatological drugs market size was valued at USD 22.59 Billion in 2024, driven by the rising emphasis on improving physical appearance across the globe. The market is expected to grow at a CAGR of 11.30% during the forecast period of 2025-2034, with the value likely to rise to USD 65.90 Billion by 2034.
Dermatological Drugs: Introduction
Dermatological drugs are used to treat skin conditions and disorders, ranging from common acne to severe diseases like skin cancer and psoriasis. They are available in numerous forms like ointments, gels, creams and oral, or injectable formulations. These drugs may reduce inflammation, redness and itching, along with treating bacterial and fungal infections.
Global Dermatological Drugs Market Analysis
The growing prevalence of skin conditions and increasing drug approvals are among the key factors driving the dermatological drugs market growth in recent years. In July 2023, the FDA approved Verrica Pharmaceuticals Inc's Ycanth for treating a viral skin infection in adults as well as children aged above 2 years. Such approvals demonstrate that the dermatological drug development will continue in the forecast period as well.
With a rising focus on meeting the needs of patients suffering from untreatable dermatological conditions, pharmaceutical organizations are continuously growing and improving their business portfolios. In October 2023, DermBoint raised USD 35.2 million in Series B for dermatological therapies. The funds were dedicated towards Phase II trials for drug candidates treating seborrheic keratoses and melasma.
The growing convergence of artificial intelligence in drug development is one of the key factors aiding the growth of dermatological drugs market demand. With the ongoing trend, companies are collaborating and acquiring artificial intelligence enabled platforms for increasing their drug development potential. For instance, in November 2023, Almirall and Absci announced a dermatological drug discovery partnership worth USD 650 million, with the help of Absci’s artificial intelligence enabled drug creation platform.
Global Dermatological Drugs Market Segmentation
Dermatological Drugs Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Diseases
The United States has been leading the dermatological drugs market share, which can be accredited to the high prevalence of skin conditions, a well-structured healthcare framework, and critical focus on research and development. Cosmetic dermatology is gaining prominence, with emphasis on cosmetic surgeries, anti-aging treatments, along with injectables, contributing to the market size.
In Europe, there is a growing trend for personalized medicine, which is fuelling the market growth in the region. With the existence of influential healthcare companies and academic institutions, there is rising development of biologic therapies. In addition, a significant portion of the geriatric population also demands better patient care. Government authorities have also been supporting market growth by setting up awareness campaigns on skincare.
Holding a substantial portion of the world’s population, the Asia Pacific region is experiencing high dermatological drugs market demand. Emerging economies like India and South Korea are witnessing improvements in the healthcare and research infrastructures to serve better treatment alternatives to patients. In addition, foreign companies are making noteworthy investments to leverage the academic talent and easy availability of resources pertaining to the area.
Global Dermatological Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Dermatological Drugs: Introduction
Dermatological drugs are used to treat skin conditions and disorders, ranging from common acne to severe diseases like skin cancer and psoriasis. They are available in numerous forms like ointments, gels, creams and oral, or injectable formulations. These drugs may reduce inflammation, redness and itching, along with treating bacterial and fungal infections.
Global Dermatological Drugs Market Analysis
The growing prevalence of skin conditions and increasing drug approvals are among the key factors driving the dermatological drugs market growth in recent years. In July 2023, the FDA approved Verrica Pharmaceuticals Inc's Ycanth for treating a viral skin infection in adults as well as children aged above 2 years. Such approvals demonstrate that the dermatological drug development will continue in the forecast period as well.
With a rising focus on meeting the needs of patients suffering from untreatable dermatological conditions, pharmaceutical organizations are continuously growing and improving their business portfolios. In October 2023, DermBoint raised USD 35.2 million in Series B for dermatological therapies. The funds were dedicated towards Phase II trials for drug candidates treating seborrheic keratoses and melasma.
The growing convergence of artificial intelligence in drug development is one of the key factors aiding the growth of dermatological drugs market demand. With the ongoing trend, companies are collaborating and acquiring artificial intelligence enabled platforms for increasing their drug development potential. For instance, in November 2023, Almirall and Absci announced a dermatological drug discovery partnership worth USD 650 million, with the help of Absci’s artificial intelligence enabled drug creation platform.
Global Dermatological Drugs Market Segmentation
Dermatological Drugs Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Diseases
- Acne
- Dermatitis
- Psoriasis
- Skin Cancer
- Rosacea
- Alopecia
- Others
- Prescription-based Drugs
- Over-the-Counter Drugs
- Topical Administration
- Oral Administration
- Parenteral Administration
- Others
- Hospitals
- Homecare
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The United States has been leading the dermatological drugs market share, which can be accredited to the high prevalence of skin conditions, a well-structured healthcare framework, and critical focus on research and development. Cosmetic dermatology is gaining prominence, with emphasis on cosmetic surgeries, anti-aging treatments, along with injectables, contributing to the market size.
In Europe, there is a growing trend for personalized medicine, which is fuelling the market growth in the region. With the existence of influential healthcare companies and academic institutions, there is rising development of biologic therapies. In addition, a significant portion of the geriatric population also demands better patient care. Government authorities have also been supporting market growth by setting up awareness campaigns on skincare.
Holding a substantial portion of the world’s population, the Asia Pacific region is experiencing high dermatological drugs market demand. Emerging economies like India and South Korea are witnessing improvements in the healthcare and research infrastructures to serve better treatment alternatives to patients. In addition, foreign companies are making noteworthy investments to leverage the academic talent and easy availability of resources pertaining to the area.
Global Dermatological Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AbbVie Inc. (Allergan PLC)
- Amgen Inc.
- Galderma
- GlaxoSmithKline Plc.
- Leo Pharma
- Johnson & Johnson
- Novartis AG
- Organon International (Merck & Co. Inc.)
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
- Sanofi
- Bausch Health Companies Inc
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- AstraZeneca
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Dermatological Drugs Market Overview
- 3.1 Global Dermatological Drugs Market Historical Value (2018-2024)
- 3.2 Global Dermatological Drugs Market Forecast Value (2025-2034)
- 4 Global Dermatological Drugs Market Landscape
- 4.1 Global Dermatological Drugs Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Dermatological Drugs Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Indication
- 4.2.3 Analysis by Route of Administration
- 5 Global Dermatological Drugs Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Dermatological Drugs Market Segmentation
- 6.1 Global Dermatological Drugs Market by Diseases
- 6.1.1 Market Overview
- 6.1.2 Acne
- 6.1.3 Dermatitis
- 6.1.4 Psoriasis
- 6.1.5 Skin Cancer
- 6.1.6 Rosacea
- 6.1.7 Alopecia
- 6.1.8 Others
- 6.2 Global Dermatological Drugs Market by Type
- 6.2.1 Market Overview
- 6.2.2 Prescription-based Drugs
- 6.2.3 Over-the-Counter Drugs
- 6.3 Global Dermatological Drugs Market by Route of Administration
- 6.3.1 Market Overview
- 6.3.2 Topical Administration
- 6.3.3 Oral Administration
- 6.3.4 Parenteral Administration
- 6.3.5 Others
- 6.4 Global Dermatological Drugs Market by End User
- 6.4.1 Market Overview
- 6.4.2 Hospitals
- 6.4.3 Homecare
- 6.5 Global Dermatological Drugs Market by Region
- 6.5.1 Market Overview
- 6.5.2 North America
- 6.5.3 Europe
- 6.5.4 Asia Pacific
- 6.5.5 Latin America
- 6.5.6 Middle East and Africa
- 7 North America Dermatological Drugs Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Dermatological Drugs Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Dermatological Drugs Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Dermatological Drugs Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Dermatological Drugs Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
- 14.1 Analysis by Trial Registration Year
- 14.2 Analysis by Trial Status
- 14.3 Analysis by Trial Phase
- 14.4 Analysis by Therapeutic Area
- 14.5 Analysis by Geography
- 15 Funding Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 AbbVie Inc. (Allergan PLC).
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisition
- 17.1.5 Certifications
- 17.2 Amgen Inc.
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisition
- 17.2.5 Certifications
- 17.3 Galderma
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisition
- 17.3.5 Certifications
- 17.4 GlaxoSmithKline Plc.
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisition
- 17.4.5 Certifications
- 17.5 Leo Pharma
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisition
- 17.5.5 Certifications
- 17.6 Johnson & Johnson
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisition
- 17.6.5 Certifications
- 17.7 Novartis AG
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisition
- 17.7.5 Certifications
- 17.8 Organon International (Merck & Co. Inc.)
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisition
- 17.8.5 Certifications
- 17.9 Pfizer Inc.
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisition
- 17.9.5 Certifications
- 17.10 Sun Pharmaceutical Industries Limited
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisition
- 17.10.5 Certifications
- 17.11 Sanofi
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisition
- 17.11.5 Certifications
- 17.12 Bausch Health Companies Inc
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisition
- 17.12.5 Certifications
- 17.13 Bristol-Myers Squibb Company
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisition
- 17.13.5 Certifications
- 17.14 F. Hoffmann-La Roche Ltd
- 17.14.1 Financial Analysis
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisition
- 17.14.5 Certifications
- 17.15 AstraZeneca
- 17.15.1 Financial Analysis
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisition
- 17.15.5 Certifications
- 18 Global Dermatological Drugs Market - Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
